# Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

> **NCT00053976** · PHASE3 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 105 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** Daclizumab
- **DRUG:** methylprednisolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00053976
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2003-11
- **Final completion:** 2004-11
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2017-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053976, "Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00053976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*